GAITHERSBURG, Md.--(BUSINESS WIRE)--Dec. 8, 2005--Gene Logic Inc. (NASDAQ:GLGC) announced today that it has entered into a drug repositioning and development agreement with Roche to seek alternative development paths for multiple Roche drug candidates. All of these drug candidates have successfully passed Phase I human clinical trials, and were discontinued in Phase II or Phase III clinical trials.
